A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

NCT ID: NCT02943564

Last Updated: 2019-12-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

658 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-01

Study Completion Date

2018-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the efficacy, safety, and tolerability of two doses of rapastinel, 225 milligrams (mg) and 450 mg, compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder, Major

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rapastinel 225 mg

Rapastinel 225 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.

Group Type EXPERIMENTAL

Rapastinel

Intervention Type DRUG

Rapastinel pre-filled syringes for weekly IV injections.

Rapastinel 450 mg

Rapastinel 450 mg weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.

Group Type EXPERIMENTAL

Rapastinel

Intervention Type DRUG

Rapastinel pre-filled syringes for weekly IV injections.

Placebo

Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo-matching rapastinel pre-filled syringes for weekly IV injections.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rapastinel

Rapastinel pre-filled syringes for weekly IV injections.

Intervention Type DRUG

Placebo

Placebo-matching rapastinel pre-filled syringes for weekly IV injections.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for MDD
* Current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Visit 1
* Have no more than partial response (\< 50% improvement) to ongoing treatment with a protocol-allowed antidepressant
* If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test.

Exclusion Criteria

* DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1
* Lifetime history of meeting DSM-5 criteria for:

1. Schizophrenia spectrum or other psychotic disorder
2. Bipolar or related disorder
3. Major neurocognitive disorder
4. Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study
5. Dissociative disorder
6. Posttraumatic stress disorder
7. MDD with psychotic features
* Significant suicide risk, as judged by the Investigator.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Naurex, Inc, an affiliate of Allergan plc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jenna Hoogerheyde

Role: STUDY_DIRECTOR

Allergan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

University of Arizona Department of Psychiatry

Tucson, Arizona, United States

Site Status

Woodland International Research Group

Little Rock, Arkansas, United States

Site Status

Woodland Research Northwest

Rogers, Arkansas, United States

Site Status

California Pharmaceutical Research Institute, Inc

Anaheim, California, United States

Site Status

ProScience Research Group

Culver City, California, United States

Site Status

Behavioral Research Specialists, LLC

Glendale, California, United States

Site Status

Synergy Clinical Research Center of Escondido

Lemon Grove, California, United States

Site Status

Pacific Research Partners; LLC.

Oakland, California, United States

Site Status

CITrials

Riverside, California, United States

Site Status

Artemis Institute for Clinical Research

San Diego, California, United States

Site Status

PCSD Feighner Research

San Diego, California, United States

Site Status

Sarkis Clinical Trials

Gainesville, Florida, United States

Site Status

Reliable Clinical Research

Hialeah, Florida, United States

Site Status

Advanced Research Institute of Miami

Homestead, Florida, United States

Site Status

Innovative Clinical Research, Inc

Lauderhill, Florida, United States

Site Status

International Research Associates, LLC

Miami, Florida, United States

Site Status

Sarkis Clinical Trials

Ocala, Florida, United States

Site Status

Medical Research Group of Central Florida

Orange City, Florida, United States

Site Status

Clinical Neuroscience Solutions, Inc

Orlando, Florida, United States

Site Status

Millenia Psychiatry & Research, Inc

Orlando, Florida, United States

Site Status

iResearch Atlanta, LLC

Decatur, Georgia, United States

Site Status

IRIS Research

Smyrna, Georgia, United States

Site Status

Great Lakes Clinical Trials

Chicago, Illinois, United States

Site Status

Alexian Brothers Center for Psychiatric Research

Hoffman Estates, Illinois, United States

Site Status

Capstone Clinical Research

Libertyville, Illinois, United States

Site Status

Phoenix Medical Research

Prairie Village, Kansas, United States

Site Status

Heartland Research Associates

Wichita, Kansas, United States

Site Status

Lake Charles Clinical Trials

Lake Charles, Louisiana, United States

Site Status

J Gary Booker, MD APMC

Shreveport, Louisiana, United States

Site Status

Pharmasite Research, Inc

Baltimore, Maryland, United States

Site Status

CBH Health

Rockville, Maryland, United States

Site Status

Boston Clinical Trials

Boston, Massachusetts, United States

Site Status

ActivMed Practices & Research, Inc.

Methuen, Massachusetts, United States

Site Status

BTC of New Bedford

New Bedford, Massachusetts, United States

Site Status

Coastal Research Associates

Weymouth, Massachusetts, United States

Site Status

Precise Research Centers

Flowood, Mississippi, United States

Site Status

Millennium Psychiatric Associates

Olivette, Missouri, United States

Site Status

Center for Emotional Fitness

Cherry Hill, New Jersey, United States

Site Status

Pharmaceutical Research Associates Inc

Marlton, New Jersey, United States

Site Status

The Medical Research Network, LLC

New York, New York, United States

Site Status

Richmond Behavioral Associates

Staten Island, New York, United States

Site Status

Richard H. Weisler, MD, PA

Raleigh, North Carolina, United States

Site Status

Patient Priority Clinical Site, LLC

Cincinnati, Ohio, United States

Site Status

The Ohio State University Department of Psychiatry

Columbus, Ohio, United States

Site Status

Charak Clinical Research Center

Garfield Heights, Ohio, United States

Site Status

Lindner Center of Hope

Mason, Ohio, United States

Site Status

Professional Psychiatric Services

Mason, Ohio, United States

Site Status

Red River Medical Research Center, LLC

Oklahoma City, Oklahoma, United States

Site Status

Sooner Clinical Research, Inc

Oklahoma City, Oklahoma, United States

Site Status

Paradigm Research Professionals

Oklahoma City, Oklahoma, United States

Site Status

Summit Research Network

Portland, Oregon, United States

Site Status

Lehigh Center for Clinical Research

Allentown, Pennsylvania, United States

Site Status

Suburban Research Associates

Media, Pennsylvania, United States

Site Status

Carolina Clinical Trials, Inc.

Charleston, South Carolina, United States

Site Status

Coastal Carolina Research Center, Inc.

Mt. Pleasant, South Carolina, United States

Site Status

Community Clinical Research, Inc.

Austin, Texas, United States

Site Status

BioBehavioral Research of Austin

Austin, Texas, United States

Site Status

Relaro Medical Trials

Dallas, Texas, United States

Site Status

El Campo Clinical Trials

El Campo, Texas, United States

Site Status

Earle Research

Houston, Texas, United States

Site Status

Red Oak Psychiatry Associates, PA

Houston, Texas, United States

Site Status

Family Psychiatry of The Wood

The Woodlands, Texas, United States

Site Status

PRA Health Sciences

Salt Lake City, Utah, United States

Site Status

Pacific Institute of Medical Sciences

Bothell, Washington, United States

Site Status

Eastside Therapeutic Resource

Everett, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

Access external resources that provide additional context or updates about the study.

http://www.AllerganClinicalTrials.com

Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact [email protected] for assistance.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RAP-MD-02

Identifier Type: -

Identifier Source: org_study_id